October 7, 2013 | PixCell Medical Technologies Ltd., which develops patented Cell-Based Diagnostics technology for the Point of Care (POC), announced that it has raised $2 million following successful completion of CE mark registration of the HemoScreen Complete Blood Count (CBC) analyzer. The finances were raised from its existing strategic investor.
Related posts
Israel Invests Millions To Help AI Comprehend Hebrew, Arabic
September 21, 2023
Cybersecurity Startup Cato Raises $238M With $3B Valuation
September 21, 2023
Israel, UK Ink Deal For Greater Innovation Collaboration
September 21, 2023
ALS Drug Receives Patent In Israel, Europe, Japan
September 20, 2023
Facebook comments